6.
Zhou K, Luo W, Liu T, Ni Y, Qin Z
. Neurotoxins Acting at Synaptic Sites: A Brief Review on Mechanisms and Clinical Applications. Toxins (Basel). 2023; 15(1).
PMC: 9865788.
DOI: 10.3390/toxins15010018.
View
7.
Renesto A, Osaki T, Osaki M, Hirai F, Campos M
. Keratoconus progression is not inhibited by reducing eyelid muscular force with botulinum toxin A treatment: a randomized trial. Arq Bras Oftalmol. 2017; 80(2):88-92.
DOI: 10.5935/0004-2749.20170022.
View
8.
Winterhoff J, Kohler S, Laskawi R
. [Botulinum toxin for the treatment of spastic entropion. Case report]. HNO. 2012; 61(7):665-7.
DOI: 10.1007/s00106-012-2626-7.
View
9.
Al-Qattan M, Al-Shanawani B, Alshomer F
. Botulinum toxin type A: implications in wound healing, facial cutaneous scarring, and cleft lip repair. Ann Saudi Med. 2013; 33(5):482-8.
PMC: 6074896.
DOI: 10.5144/0256-4947.2013.482.
View
10.
Lennerstrand G, Nordbo O, Tian S, Ali T
. Treatment of strabismus and nystagmus with botulinum toxin type A. An evaluation of effects and complications. Acta Ophthalmol Scand. 1998; 76(1):27-7.
DOI: 10.1034/j.1600-0420.1998.760106.x.
View
11.
Niyaz L, Yeter V, Beldagli C
. Success rates of botulinum toxin in different types of strabismus and dose effect. Can J Ophthalmol. 2022; 58(3):239-244.
DOI: 10.1016/j.jcjo.2021.12.002.
View
12.
Iannitti T, Palmieri B, Aspiro A, Cerbo A
. A preliminary study of painless and effective transdermal botulinum toxin A delivery by jet nebulization for treatment of primary hyperhidrosis. Drug Des Devel Ther. 2014; 8:931-5.
PMC: 4106921.
DOI: 10.2147/DDDT.S60389.
View
13.
Meurens F, Carlin F, Federighi M, Filippitzi M, Fournier M, Fravalo P
. type C, D, C/D, and D/C: An update. Front Microbiol. 2023; 13:1099184.
PMC: 9849819.
DOI: 10.3389/fmicb.2022.1099184.
View
14.
Whittaker K, Matthews B, Fitt A, Sandramouli S
. The use of botulinum toxin A in the treatment of functional epiphora. Orbit. 2003; 22(3):193-8.
DOI: 10.1076/orbi.22.3.193.15622.
View
15.
Lolekha P, Choolam A, Kulkantrakorn K
. A comparative crossover study on the treatment of hemifacial spasm and blepharospasm: preseptal and pretarsal botulinum toxin injection techniques. Neurol Sci. 2017; 38(11):2031-2036.
DOI: 10.1007/s10072-017-3107-2.
View
16.
Johnson E, Dressler D
. Contrarian Botox pioneer remembered. Nature. 2022; 603(7899):32.
DOI: 10.1038/d41586-022-00596-4.
View
17.
Goschel H, Wohlfarth K, Frevert J, Dengler R, Bigalke H
. Botulinum A toxin therapy: neutralizing and nonneutralizing antibodies--therapeutic consequences. Exp Neurol. 1997; 147(1):96-102.
DOI: 10.1006/exnr.1997.6580.
View
18.
Singh S, Ali M, Paulsen F
. A review on use of botulinum toxin for intractable lacrimal drainage disorders. Int Ophthalmol. 2017; 38(5):2233-2238.
DOI: 10.1007/s10792-017-0661-9.
View
19.
Whitcup S
. The History of Botulinum Toxins in Medicine: A Thousand Year Journey. Handb Exp Pharmacol. 2019; 263:3-10.
DOI: 10.1007/164_2019_271.
View
20.
Wabbels B, Jost W, Roggenkamper P
. Difficulties with differentiating botulinum toxin treatment effects in essential blepharospasm. J Neural Transm (Vienna). 2011; 118(6):925-43.
PMC: 3104001.
DOI: 10.1007/s00702-010-0546-9.
View